By KARL WILSON in Sydney | China Daily | Updated: 2020-12-25 10:30 Share CLOSE A health worker shows a malaria rapid test kit after collecting blood sample from a resident during a drive to prevent the spread of mosquito-borne diseases in Ahmedabad, India, Oct 26, 2018. [Photo/Agencies]
Efforts against perennial killer take back seat, with spike in deaths feared
COVID-19 could result in thousands of deaths from malaria across the Pacific region, with health experts warning that the pandemic response could derail previously planned efforts to control the mosquito-borne disease.
Malaria continues to extract a heavy toll on human lives, killing more than 400,000 a year globally, with most of the victims being children under five. Africa, Asia, and the Pacific are particularly prone to the disease.
How HIV Research Laid the Foundation for Covid Vaccines
Scientific techniques developed in the ongoing fight against AIDS helped scientists combat the new coronavirus As states and hospitals in the U.S. race to roll out the first Covid-19 vaccines, WSJ’s Daniela Hernandez hears from a hospital administrator and immunization expert about the logistical challenges involved in this first phase of the vaccination process. Photo: Victoria Jones/Zuma Press By Dec. 24, 2020 9:51 am ET
People are receiving Covid-19 vaccines less than a year after public health authorities discovered SARS-CoV-2, the deadly new coronavirus. How did it happen so quickly? In part, the world can thank decades of frustrating and often fruitless research to find a vaccine for Human Immunodeficiency Virus or HIV, the virus that causes AIDS. Many of the new technologies and approaches employed to create potent Covid-19 vaccines and therapies trace their origins to the desperate se
Share this article
Share this article
Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal
Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the nose and throat by up to 96%; also found to be effective against rhinovirus (common cold), the
predominant cause of the common cold and exacerbations of chronic respiratory diseases including asthma and COPD
Mode of action complementary to COVID-19 vaccines, once weekly nasal spray to play significant role in reducing COVID-19 community transmission and disease progression in at risk populations
S. Korea s Nafabeltan gets clinical approval for COVID-19 treatment in Australia |
Nafabeltan, which is currently used as a blood anticoagulant and acute pancreatitis treatment. (Chong Kun Dang Pharmaceutical Corp.)
South Korean drug firm Chong Kun Dang Pharmaceutical Corp. said Monday that it has won approval from Australia s drug authorities to begin a phase three clinical trial for coronavirus treatment with its acute pancreatitis drug.
The drug, Nafabeltan, will be administered to patients as part of the Australian government-led clinical study to find a COVID-19 treatment. The drug is currently used as a blood anticoagulant and acute pancreatitis treatment.
The Australian COVID-19 Trial, also known as ASCOT, is a randomized control trial that involves 2,500 patients in over 60 hospitals across the country alongside 12 hospitals in New Zealand with the participation of global pharmaceutical firms.